Use of Queatiapine in Treatment of Unremitting Anxiety: A Case Report of Schizophrenia Prodrome
Objective: A 21-year-old man who presented with a 17-month history of unremitting anxiety associated with panic attacks was studied. Result: The anxiety with panic attacks did not abate with escitalopram 15 mg nocte and alprazolam 0.5 mg tds. At month 3, the patient reported low mood and unexplai...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Japan International Cultural Exchange Foundation
2016
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/44056/1/Use%20of%20Queatiapine%20in%20Treatment%20of%20Unremitting%20Anxiety.pdf http://eprints.usm.my/44056/ http://www.seronjihou.co.jp/IMJ/backnumber-IMJ.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universiti Sains Malaysia |
| Language: | English |
| Summary: | Objective: A 21-year-old man who presented with a 17-month history of unremitting anxiety associated with panic attacks
was studied.
Result: The anxiety with panic attacks did not abate with escitalopram 15 mg nocte and alprazolam 0.5 mg tds. At month 3,
the patient reported low mood and unexplained sexual arousal in addition to the unremitting anxiety symptoms. His condition
fairly improved with addition of quetiapine. At month 17, transition to psychotic disorder occurred when the patient experienced
hallucinations for the first time. Quetiapine was increased to 500 mg nocte and the anxiety symptoms improved tremendously
before he relapsed 6 months later due to poor compliance.
Conclusion: Unremitting anxiety with depression can be a dominant feature during the schizophrenia prodrome. Atypical
antipsychotic quetiapine is an interesting treatment option due to its status as approved adjunctive treatment for major depressive
disorder and promising efficacy for generalized anxiety disorder. |
|---|